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ABSTRACT 
microRNAs (miRNAs) are a class of epigenetic post-transcriptional regulators. These short 
(~22 nucleotides) non-coding RNAs can potently reduce protein abundance through direction 
of the RNA-induced silencing complex to targeted genes. Ultimately, miRNAs will reduce 
protein levels of target genes through mechanisms involving either inhibition of protein 
translation or destabilization and cleavage of target gene mRNA molecules. 
miRNAs are implicated in the regulation of several cellular processes, including 
growth, differentiation, and metabolism. The expression of miRNAs is altered in several 
clinical conditions including cancer, obesity, and diabetes. In this thesis, the aim was to 
elucidate how miRNAs are regulated in human skeletal muscle during three conditions, 
including in vitro skeletal muscle development, in type 2 diabetic patients, and following 
endurance exercise training. After identifying miRNAs that have altered expression in the 
aforementioned conditions, an additional aim was to characterize the functional effects of 
these miRNAs, including effects on target gene abundance and regulation of cellular 
metabolism.  
In Study I, miRNA expression was determined during human skeletal muscle cell 
differentiation with 48-hour resolution. Transcriptomic miRNA expression profiles of 
proliferative and differentiated cells were overlapped with gene expression alterations to 
identify reciprocal miRNA-mRNA expression patterns. Using this approach, miRNA-
centered regulatory networks involved in in vitro human skeletal muscle development were 
predicted. miR-30b and miR-30c were among those differentially regulated miRNAs for 
which regulatory networks were modelled. 
In Study II, increased expression of miR-29a and miR-29c was identified in skeletal 
muscle from type 2 diabetic patients. Specifically, these miRNAs were expressed to a greater 
extent in type 2 diabetes. Thereafter these miRNAs were identified to induce insulin 
resistance and disturbances in glucose metabolism in human and mouse skeletal muscle. 
Several genes implicated in regulation of glucose and lipid metabolism were identified to be 
sensitive to altered miR-29 expression, including hexokinase 2. 
In Study III, miR-19b-3p and miR-107 were found to be induced in human skeletal 
muscle following 14 consecutive days of endurance exercise. The roles of these two miRNAs 
in the regulation of mRNA abundance and metabolic traits associated with skeletal muscle 
adaptation to endurance exercise training were determined. miR-19b-3p and miR-107 were 
identified to potently increase insulin sensitivity and glucose metabolism in human skeletal 
muscle cells, whereas functions of miR-19b-3p were also conserved in vivo and in in vitro 
models of mouse skeletal muscle. 
Together, these studies highlight roles of skeletal muscle miRNAs in post-
transcriptional regulation of gene expression and modifications of insulin sensitivity in 
conditions such as type 2 diabetes and following endurance training.  
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1 INTRODUCTION 
1.1 REGULATION OF POST-TRANSCRIPTIONAL EVENTS BY NON-CODING 
RNAS 
1.1.1 Transcriptional homeostasis and epigenetics 
Homeostasis is the regulation and control of an organism’s internal state in response to 
alterations in the external environment. Evolution has led to numerous systems that keep 
physiological processes under tight control to ensure survival of the organism. Homeostatic 
regulation is dynamic, keeping a system within a close range of a biological set point. For 
example, blood glucose fluctuates over the course of the day, but returns in the fasted state to 
~5 mmol/L in healthy humans. Homeostatic mechanisms are observed at various scales in 
biology. There is complex crosstalk between different tissues and cell types in multicellular 
organisms. Within individual cells, examples of homeostatic control include maintenance of 
membrane lipid composition, progression through the cell cycle, substrate metabolism, RNA 
transcription, and protein translation. 
The central dogma of molecular biology was postulated in the 1950s and describes 
the flow of information in biological systems [1]. The flow can simply be summarized as 
DNA is transcribed into RNA and then RNA is translated into protein. The tight control of 
this stepwise progression in the cell maintains the informational integrity in DNA while 
producing necessary proteins in response to homeostatic challenges. Transcription and 
translation of a gene into its functional unit is regulated at multiple levels. All diploid cells in 
an organism share a nearly identical DNA sequence. Nevertheless, there is a myriad of 
different cell types in the human body. This diversity in cell types arises due to differential 
expression of functional units: proteins and non-coding RNAs (ncRNAs). Also, the normal 
function of cells requires proper transcriptional responses to changes in the external 
environment. Several regulatory mechanisms function to sustain this diversity including 
epigenetic modifications, transcription factor activation, post-transcriptional processes, and 
various post-translational modifications. 
Epigenetics (epi-, Greek prefix meaning “over, around”) describes changes in gene 
function that do not involve alterations of the genetic sequence. Epigenetic control 
mechanisms include histone modifications, DNA methylation, and ncRNA. Histones are 
proteins which the DNA is coiled around to form nucleosomes, facilitating the packing of 
large DNA molecules into chromosomes [2]. Histone proteins ensure selective accessibility 
of functional units within DNA (e.g., enhancers, promoters, and open reading frames) for the 
transcriptional machinery. Histones can be modified by different post-translational 
modifications, including methylation, acetylation, and phosphorylation. These alterations 
regulate accessibility to the genome and create a so-called ‘histone code’ [3]. The DNA of a 
cell can also be methylated on cytosine nucleotides, specifically in CpG sites, creating 5-
methylcytosine [2]. The location being methylated within the genome ultimately determines 
the functional effects of such modifications. For example, methylation of cytosine in gene 
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promoters causes recruitment of proteins, including histone modifying-proteins, which 
repress transcription [2]. Another epigenetic mechanism to regulate gene expression and 
translation is through ncRNAs. ncRNAs are a diverse family of RNA species that regulate 
gene expression, protein translation and genome stability. 
1.1.2 Overview of non-coding RNAs 
The human genome consists of ~3 billion base pairs and 62% of the DNA is transcribed into 
RNA molecules [4]. While only 1.5% of the DNA gives rise to protein coding exons, a large 
part of the transcribed RNA is of a non-coding nature. Whether all of these ncRNA molecules 
have functional potential remains undetermined. Nevertheless, several of the transcribed 
ncRNA are well characterized and known to be functional, including structural ncRNAs such 
as ribosomal RNA (rRNA) and transfer RNA (tRNA) that are necessary for protein synthesis. 
Thus, besides coding for proteins, a large part of the human DNA gives rise to functional 
ncRNA molecules. 
Several different classes of ncRNAs exist and these can be divided into two groups 
based on their size: short (<200 nt) and long (≥200 nt) ncRNAs. Short ncRNAs can further be 
divided into multiple different subclasses, some of which are listed in Table 1. One such 
class of short ncRNAs is the focus of this thesis: microRNAs (miRNAs). 
Table 1. Examples of short non-coding RNAs 
 
Type of short ncRNA Abbreviation Length (nt) Function 
Small nuclear RNA snRNA ~150 Splicing and maturation of pre-mRNAs [5] 
Small nucleolar RNA snoRNA 60–300* Directs chemical modifications of RNA molecules [5] 
Short hairpin RNA shRNA 20–25 Artificial RNA molecules used to silence genes [6] 
Small interfering RNA siRNA 20–25 
Post-transcriptional regulation 
and antiviral defense 
mechanism [5] 
microRNA miRNA ~22 Post-transcriptional regulation of gene expression [7] 
Piwi-interacting RNA piRNA ~30 
Silencing of transposable 
elements and important for 
genome stability [5] 
*Some snoRNAs are classified as long non-coding RNAs. 
1.1.3 miRNAs as post-transcriptional regulators 
miRNAs are about 22 nucleotides long and act as post-transcriptional regulators of gene 
expression [7]. This ncRNA family was identified in the early 1990s when two groups of 
researchers showed that C. elegans development was controlled by the non-coding lin-4 gene 
that regulates Lin-14 protein abundance dependent on the lin-14 3’-untranslated region 
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(UTR) [8, 9]. During the following years, additional short ncRNAs were discovered, which 
have conserved sequences in the human genome [10, 11]. These short ncRNAs were named 
miRNAs. In the end of the 1990s and beginning of the 2000s, the functional aspects of post-
transcriptional regulation by miRNAs were elucidated [12]. 
miRNAs ultimately act to reduce protein abundance of targeted transcripts. miRNAs 
are transcribed from the nuclear DNA into primary miRNAs (pri-miRNAs) that can be 100s 
of base-pairs long and have a hairpin structure [13]. See Figure 1 for an overview of miRNA 
biogenesis and mode of action. In the nucleus, the pri-miRNA is cleaved at the base of the 
stem-loop into a precursor miRNA (pre-miRNA) by the RNase III protein Drosha, which is 
part of the Microprocessor complex [14, 15]. The pre-miRNA still contains its characteristic 
hairpin structure, which is important for later stages of miRNA maturation and function. 
Following cleavage, the pre-miRNA is exported from the nucleus by Exportin-5 [16]. In the 
cytosol, the pre-miRNA is further cleaved by the RNase III enzyme Dicer, resulting in a 
miRNA:miRNA duplex [17]. One of the strands, the guide strand, is introduced into the 
RNA-induced silencing complex (RISC) [18]. The selection of the guide strand is not 
random. Factors influencing this selection include strand stability at the 5’end of the 
miRNA:miRNA duplex, as well as regulation by proteins involved in miRNA maturation 
including Dicer and RISC-associated proteins [19]. The miRNA strand in RISC will guide 
the complex to target genes through direct Watson-Crick base pairing between the miRNA 
and 3’UTRs of targeted mRNAs. Nucleotides 2–8 in the 5’ end of the miRNA, known as the 
seed region, is under higher selective pressure compared to other nucleotides of miRNAs 
[20]. The seed region of the miRNA is the most important component for guidance of the 
RISC to target genes. Within RISC, a large multiprotein complex, the protein Argonaut 
(AGO) binds the miRNA and guides RISC to target mRNAs [21]. This guidance will result 
in decreased translation of protein from the target gene due to either destabilization and 
cleavage of the mRNA or inhibition of protein translation [13]. Cleavage of targeted mRNA 
requires a catalytically active AGO protein (i.e., AGO2 in humans) and also a high sequence 
complementary between the miRNA and mRNA target [13, 22]. Inhibition of protein 
translation of target genes by miRNA-loaded RISC can be achieved by prevention of 
initiation or by termination of ongoing protein translation [23, 24]. In contrast to earlier 
beliefs that human miRNAs mainly worked through inhibition of translation, miRNAs in 
mammals predominantly act to reduce mRNA abundance [25]. In humans, approximately 
60% of protein-coding genes have conserved sites for miRNA binding, implicating that 
miRNAs can alter the expression of a majority of human coding transcripts [26]. Thus, 
miRNAs are potent post-transcriptional regulators that cause decreased abundance of target 
genes. 
Conservation of miRNA sequences between species also suggests conservation of 
regulated targets and functions. The machinery used for miRNA maturation and target 
recognition is well conserved in eukaryotes and believed to have evolved initially as a 
defence mechanism against viruses [27]. The evolution of RNA interference-mechanisms 
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Figure 1. Overview of miRNA maturation, function and target recognition. miRNAs are 
transcribed as primary miRNAs (pri-miRNA) and processed within the nucleus to a precursor miRNA 
(pre-miRNA) by the Microprocessor complex. Thereafter, the pre-miRNA is exported from the 
nucleus by Exportin-5 into the cytoplasm where Dicer cleaves the pre-miRNA to a miRNA duplex. 
The guide strand will get incorporated into the RNA-induced silencing complex (RISC), while the 
other strand is degraded. The miRNA will guide RISC to targeted mRNAs and bind through Watson-
Crick complementary binding, which results in either mRNA degradation or translational repression, 
ultimately decreasing translation of protein of miRNA target genes. 
also permitted improved possibilities for fine-tuning gene expression and regulation of 
cellular functions. Whereas the machinery for RNA interference is conserved in eukaryotes, 
miRNAs are not conserved between the animal and plant phyla, indicating that they have 
evolved independently. Whereas animal miRNAs bind targets through incomplete 
complementarity, plant miRNAs often show full complementarity to their targets resulting in 
mRNA decay [13]. In animals, several miRNA families are conserved from worms to 
humans [28]. Furthermore, some miRNAs have arisen within distinct branches of evolution; 
for example, there are primate- and human-specific miRNAs [29]. Evolutionary young 
miRNAs were found to show predominant expression in neural tissues, implicating that 
young miRNAs might have contributed to the evolution of more complex mammalian brains 
[29]. Additionally, conserved miRNA target sites within target gene 3’UTRs are more likely 
to be functional and physiologically relevant [30]. In total, 2,693 mature miRNA sequences 
have been identified in humans (miRbase, release 22 (March 2018)). The number of miRNAs 
in animal genomes correlates to DNA size, and thus with genomic complexity [29]. With the 
 5 
 
knowledge that ~60% of protein-coding genes in humans have conserved miRNA target sites 
[26], miRNAs are conserved post-transcriptional regulators of target abundance that have co-
evolved together with an increased complexity in the regulation of the mammalian genome. 
1.2 SKELETAL MUSCLE 
1.2.1 Overview of skeletal muscle function and morphology 
Skeletal muscle is needed for posture, locomotion, and ultimately for survival. The tissue 
accounts for approximately 40-45% of body mass in healthy humans and play a vital role in 
energy metabolism [31]. Skeletal muscle is composed of multinucleated fibers that contain 
myofibrillar proteins including actin and myosin organized into filaments. Together, repeated 
units of thin actin and thick myosin filaments create the functional contractile apparatus of 
skeletal muscle: the sarcomere. In response to motor neuron activation, Ca2+ is released from 
intracellular stores and will through regulatory proteins trigger muscle contraction due to 
sliding filaments and cross-bridging [32, 33]. In response to a spike in Ca2+, myosin motor 
proteins will hydrolyse ATP leading to conformational changes of the protein that ultimately 
shortens the sarcomere. The conformational changes of myosin and reshuffling of 
intercellular Ca2+ are energy demanding, and, thus, skeletal muscle is a main contributor to 
resting metabolic rate in mammals [34, 35]. 
Skeletal muscle tissue consists of different fiber types that can be characterized by 
specific contractile or metabolic properties [31]. Basically, there are three fiber types: type I 
fibers (slow-twitch; oxidative), type IIa fibers (fast-twitch; oxidative), and type IIx fibers 
(fast-twitch; glycolytic). Type I fibers are oxidative and used during low-intensity exercise, 
while type II fibers are more glycolytic and active for short bursts of intense activity. Skeletal 
muscle fiber type composition is sensitive to exercise interventions and disease states. 
Athletes in sports that demand endurance (aerobic exercise) have higher relative amounts of 
type I fibers, whereas athletes in sports that require strength and power (resistance) have more 
type II fibers [31, 36]. Additionally, changes in fiber type composition can occur in response 
to endurance and resistance exercise [36]. For example, endurance training increases the 
relative amount of type I fibers while decreasing type IIx fibers [37, 38]. Insulin resistance is 
associated with reduced capillary density and abundance of type I fibers in humans [39]. For 
example, in type 2 diabetic patients there is a reduction in slow oxidative fibers and a 
concomitant increase in fast glycolytic fibers [40]. These findings are of clinical importance 
since larger relative amounts of type I fiber in skeletal muscle are associated with increased 
expression of the contraction and insulin-responsive glucose transporter GLUT4 and capacity 
for insulin-stimulated glucose transport [41, 42]. 
miRNAs have been implicated in fiber type specification. Three genes encoding for 
myosin heavy chain (MYH) isoforms, MYH6, MYH7, and MYH7B, encode intronic miRNAs, 
miR-208a, miR-208b, and miR-499, respectively [43]. MYH6/miR-208a are expressed in 
cardiac muscle, MYH7/miR-208b in skeletal muscle type I fibers, and MYH7B/miR-499 in 
both cardiac muscle and skeletal muscle type I fibers. These miRNAs are potent regulators of 
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skeletal muscle fiber type specification in mice, as double knockout of miR-208b/miR-499 in 
skeletal muscle reduce the number of type I fibers [43]. These miRNAs are required for part 
of the transcriptional networks that specify skeletal muscle fiber type [44]. Thus, skeletal 
muscle characteristics are linked to energy metabolism in conditions such as exercise and 
insulin resistance, and are influenced by miRNA-dependent regulatory mechanisms. 
1.2.2 Skeletal muscle development 
Skeletal muscle consists of myofibers responsible for contraction, as previously mentioned. 
Several other cell types are also present in skeletal muscle tissue, including progenitor cells 
(satellite cells) [45]. In adult skeletal muscle these progenitors are quiescent but can respond 
to stressors, such as contractile activity or injury to myofibers, to re-enter the cell cycle and 
regenerate muscle tissue. For example, hypertrophy of skeletal muscle in response to 
resistance exercise is linked to the ability of satellite cell activation [46, 47]. Furthermore, 
satellite cells are required for regeneration of skeletal muscle following toxin-induced injury 
[48]. Satellite cells represent an important cell type in skeletal muscle and are needed for its 
regenerative and plastic potential. 
An extensively used tool to study skeletal muscle development and regeneration is the 
isolation of satellite cells from either human skeletal muscle biopsies or intact muscle from 
mice. These cells can proliferate and differentiate into mature multinucleated myotubes in 
vitro. Several different transcription factors, including Paired Box 3 (PAX3) and Paired Box 
7 (PAX7), are determinants for the myogenic lineage and the proliferation of satellite cells 
[49]. PAX3 is essential for embryogenic myogenesis [50], whereas PAX7 is required for 
satellite cell specification and adult skeletal muscle regeneration [48, 51]. Activation of 
myogenic precursors stimulates their re-entering of the cell cycle to start proliferating. The 
commitment of satellite cells to differentiation into multinucleated myotubes is under the 
control of other transcription factors known as myogenic regulatory factors (MRFs), 
including myogenic differentiation (MYOD), myogenin (MYOG), and myogenic factor 5 
(MYF5) [49]. These regulators promote differentiation of satellite cells by controlling 
expression of multiple myogenic genes. Since loss-of-function studies of MYF5 and MYOD 
in mice result in ablated skeletal muscle formation, these genes are considered determination 
factors that are required for myogenic identity [52]. MYF5 and MYOD are also upstream 
regulators of later MRFs, such as MYOG, that are important for terminal myotube 
differentiation and formation as MYOG-deficiency is postnatally lethal in mice due to muscle 
deficiency [53]. Nevertheless, other functional regulators of skeletal muscle formation exist 
and include miRNAs. 
1.2.3 miRNA-regulation of skeletal muscle development 
Evidence for regulatory roles of miRNAs in skeletal muscle development and regeneration 
comes from models where miRNA maturation is disturbed. Skeletal muscle-specific Dicer 
ablation in mice reduces the expression of several miRNAs and causes perinatal death, which 
associates with reduced skeletal muscle mass [54]. Additionally, conditional knockout of 
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Dicer in satellite cells of mice results in spontaneous re-entering of the cell cycle causing 
impaired injury-induced skeletal muscle regeneration [55]. Thus, normal biogenesis of 
miRNAs in satellite cells and in mature muscle is required for skeletal muscle plasticity and 
development. 
Several miRNAs show enriched or specific expression in muscle tissue (skeletal and 
cardiac muscle) and are therefore termed ‘myomiRs’ [56]. Examples of myomiRs include 
miR-1, miR-133a/b, miR-206, miR-208a/b, and miR-499. Duplication of some of these 
miRNAs during evolution has endowed them with similar sequences, and are located in 
duplicate locations of the genome. For example, miR-1 and miR-206 differ in only four 
nucleotides, but share identical seed sequences, and thus also similar, but not identical, targets 
[57]. Several of the myomiRs are induced upon skeletal muscle differentiation by regulation 
of different MRFs [58-60]. miR-1 and miR-206 are induced during differentiation, and target 
repressors of skeletal muscle differentiation, including histone deacetylase 4, PAX3, and 
PAX7 [59, 61, 62]. Nevertheless, while in vitro effects of these miRNAs on skeletal muscle 
cell differentiation are clear, ablation of miR-1-2 or miR-206 in mice does not disturb 
embryonic development of skeletal muscle [63, 64]. The lack of functional effects on skeletal 
muscle development in these models could indicate methodological differences of studying 
this process when using in vitro cell cultures or in vivo models of embryonic muscle 
development. Another plausible explanation for the lack of effects are that miR-1 and miR-
206 share the same seed sequence and could thus compensate for ablation of one of the 
myomiR members. Evidence pointing towards the latter explanation comes from experiments 
performed on D. melanogaster which only have a single copy of miR-1 and lack miR-206. 
Ablation of miR-1 in flies cause deformed musculature in larvae [65]. Furthermore, deletion 
of miR-206 disturbed post-embryonic regeneration of muscle in response to injury and 
exacerbate dystrophic symptoms in mice [64, 66]. Additionally, miR-1 and miR-133a also 
modulate differentiation-associated increases in mitochondrial function and abundance [67]. 
Thus, members of the myomiRs, including miR-1 and miR-206, are critical regulators of 
skeletal muscle development and regeneration. 
Non-skeletal muscle-enriched miRNAs are also involved in processes related to 
skeletal muscle development and differentiation. Expression of several miRNAs is altered 
upon skeletal muscle cell proliferation and differentiation as determined by transcriptomic 
approaches [55, 68-72]. Whereas myomiRs are among the miRNAs with the largest relative 
expressional changes, numerous other miRNAs are altered during skeletal muscle cell 
proliferation and differentiation. Examples of such miRNAs that have functional effects 
during myogenesis in vitro include miR-20a [73], miR-26a [70], and miR-30 [74]. Regulation 
of skeletal muscle cell differentiation is not only restricted to miRNAs among the ncRNA 
family. For example, numerous long ncRNAs are implicated in the regulation of skeletal 
muscle differentiation and myogenesis [75, 76]. Interestingly, some long ncRNAs regulate 
skeletal muscle differentiation acting as ‘sponges’, endogenous decoys, for myogenic 
miRNAs [77-79]. These findings further support an important role for miRNAs in regulation 
of myogenesis. 
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1.3 GLUCOSE HOMEOSTASIS AND TYPE 2 DIABETES 
1.3.1 Regulation of whole-body glucose homeostasis and skeletal muscle 
glucose metabolism 
Blood glucose levels are tightly regulated and under homeostatic control in fed and fasted 
conditions. This regulation is complex and involves several tissues, including the brain, 
gastrointestinal tract, pancreas, liver, adipose, and skeletal muscle. The brain regulates energy 
metabolism and feeding behaviors through regulatory centers in the hypothalamus and brain 
stem [80]. These centers receive information, often in the form of hormonal signals, from the 
peripheral tissues about energy availability. One such example is the hormone leptin, which is 
released from adipose tissue when energy supply is high and signals to satiety centers in the 
brain. The brain can thereby regulate feeding behaviors and stimulate food intake. Ingested 
carbohydrates (e.g., starch and sucrose) are broken down into monosaccharides, the most 
common in our diet being glucose. The presence of monosaccharides will stimulate release of 
several gastrointestinal hormones such as gastric inhibitory protein (GIP) and glucagon-like 
peptide 1 (GLP1) [81]. An increase in circulating blood glucose following a meal is sensed 
by the pancreas [82]. Endocrine cells in the pancreas, namely α- and β-cells, produce 
glucagon and insulin, respectively. These hormones are major regulators of whole-body 
glucose homeostasis. With increased blood glucose, β-cells release insulin into the blood 
stream to reduce levels of circulating glucose. Primary target tissues for insulin action are 
liver, adipose, and skeletal muscle, as insulin stimulation will increase glucose uptake, 
glycolysis, glycogen synthesis, and lipogenesis in these tissues [83]. As previously 
mentioned, GIP and GLP1 are released into the blood in response to monosaccharides in the 
gastrointestinal tract, and these hormones stimulate insulin-release from β-cells. The actions 
of GLP1 and GIP are thought to account for about 50% of the insulin released after a meal, 
and thus a large part of the insulin-stimulated glucose disposal [81]. Under fasting conditions, 
where glucose levels are low, glucagon is released to activate hepatic glucose production 
(HGP) by promoting gluconeogenesis and glycogenolysis in the liver, leading to an elevation 
in blood glucose levels [82]. Thus, glucose homeostasis is tightly controlled by numerous 
tissues and endocrine regulatory nodes. 
Skeletal muscle has an important role in the regulation of whole-body energy 
metabolism and glucose homeostasis. Skeletal muscle tissue is a main contributor to resting 
metabolic rate [35]. Skeletal muscle also serves as a pool of energy reserves in states of 
starvation when amino acids can be released to sustain HGP. Skeletal muscle production of 
lactate through anaerobic glucose metabolism can also provide substrates for HGP [84]. 
Additionally, skeletal muscle absorbs ~25% of ingested glucose in the postprandial state and 
is estimated to be responsible for ~85% of insulin-stimulated glucose uptake [85, 86]. This 
effect is mediated by insulin binding to its receptor on the skeletal muscle plasma membrane, 
which activates a signaling cascade involving insulin receptor substrate (IRS), 
phosphoinositide 3-kinase (PI3K), and protein kinase B (PKB/Akt) activation [83]. 
Downstream of Akt, several different branches of insulin-signaling are responsible for 
insulin’s functional effect in skeletal muscle. For example, Akt inhibits glycogen synthase 
 9 
 
kinase 3 (GSK3) and activates mammalian target of rapamycin (mTOR) resulting in 
increased glycogenesis and protein synthesis, respectively. Insulin-stimulated glucose uptake 
in skeletal muscle is regulated by Akt-dependent inhibition of TBC1 domain family member 
4 (TBC1D4/AS160), thus permitting GLUT4-containing vesicles to fuse with the plasma 
membrane, which results in increased glucose transport. Thus, skeletal muscle contributes to 
glucose homeostasis due to its great capacity to clear glucose from the circulation in response 
to insulin-stimulation (see Figure 2 for an overview of skeletal muscle insulin-signaling). 
Figure 2. Schematic of insulin and contraction-induced glucose transport. Insulin and contraction 
induce skeletal muscle glucose uptake through different mechanisms. Insulin will bind to the insulin 
receptor (IR) causing autophosphorylation of intracellular domains of the receptor. Insulin receptor 
substrate 1 (IRS1) will bind and become activated through phosphorylation at serine and tyrosine 
residues. This will cause phosphoinositide 3-kinase (PI3K) to interact with IRS1 resulting in PI3K 
activation and phosphorylation of the phospholipid phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2) 
generating phospholipid phosphatidylinositol 3,4,5-trisphosphate (PI(3,4,5)P3). PI(3,4,5)P3 will recruit 
Akt/PKB (Akt) to the plasma membrane resulting in phosphorylation of Thr308 and Ser473, thus 
activating Akt. Insulin-stimulated Akt activation is responsible for several of insulin’s functional 
effects in skeletal muscle. Akt will phosphorylate glycogen synthase kinase 3 (GSK3) at Ser21/9 
(GSK3αSer21 and GSK3βSer9), and this phosphorylation will relieve GSK3-dependent inhibitory 
phosphorylation of glycogen synthase (GS) at Ser641 ultimately increasing glycogen synthesis. Akt 
will also phosphorylate and inhibit TBC1 domain family member 4 (TBC1D4/AS160) through 
phosphorylation at Thr642, resulting in inhibition of TBC1D4’s GTPase activating domain that, when 
activated, keeps several different Ras-related proteins (RAB) inhibited. Thus, when Akt inhibits 
TBC1D4, RAB proteins will get activated, ultimately causing intracellular pools of GLUT4-
containing vesicles to fuse with the plasma membrane. GLUT4 will then be able to transport glucose 
across the plasma membrane. During contraction, several different contraction-induced mechanisms 
will cause phosphorylation at different residues of TBC1D1, including Ser237, resulting in inhibition of 
TBC1D1 GTPase activity. Similarly to TBC1D4, inhibition of TBC1D1 will cause activation of RAB 
proteins resulting in GLUT4 translocation. Following transport, glucose gets phosphorylated by 
hexokinase 2 (HK2) to generate glucose-6-phosphate (G6P). G6P is trapped intracellularly through 
phosphorylation, and can be metabolized by mitochondria or stored as glycogen. 
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1.3.2 Type 2 diabetes and insulin resistance 
Disturbed homeostasis of glucose is observed in states of insulin resistance, such as in 
patients with type 2 diabetes (T2D). Prevalence of obesity and T2D has dramatically 
increased during the last decades. In 2016, 650 million adults were obese and over 380 
million children and adolescents were overweight or obese [87]. Thus, worldwide obesity has 
close to tripled in the last 40 years. As obesity is a well characterized risk factor for the 
development of T2D [88], the prevalence of diabetes has also increased to 422 million adults 
[89]. Furthermore, by 2045 the number of individuals with diabetes is estimated to increase 
by 50% [90]. The rise in obesity and T2D coincides with increases in a sedentary life style, 
reduced physical activity, and increased caloric intake. Complications arising due to diabetes 
include a higher risk for cardiovascular disease [91]. Furthermore, diabetes is the sixth 
leading cause of death [92], and thus shortens life expectancy. 
The etiology of T2D is complex and involves multiple organs in the body. T2D is 
defined as having fasting blood glucose ≥7.0 mmol/L or blood glucose ≥11.1 mmol/L two 
hours after an oral glucose tolerance test [93]. Major determinants of disease progression are 
disturbed release of insulin from the insulin producing cells in the pancreases and insulin 
resistance in peripheral tissues. Disturbed β-cell function and apoptosis is observed before 
clinical development of T2D, resulting in decreased insulin release in response to elevated 
blood glucose [94]. Furthermore, the gastrointestinal-induced glucose disposal that is 
mediated through GIP and GLP1 is disturbed in T2D due to a defective β-cell response [95]. 
Peripheral insulin resistance in liver, adipose, and skeletal muscle disturbs whole-body 
glucose and lipid metabolism. Increased adiposity with obesity interferes with insulin’s anti-
lipolytic effect on adipose tissue, which results in excessive amount of circulating free fatty 
acids and ectopic lipid storage in liver and skeletal muscle, that negatively regulate insulin 
sensitivity through different mechanisms [96]. In addition, insulin resistance in adipose tissue 
is associated with increased tissue inflammation, further disturbing adipose tissue glucose and 
lipid metabolism [97]. In liver, insulin fails to inhibit gluconeogenesis and thus HGP in T2D, 
resulting in disproportionate glucose release from hepatocytes even in the fed state [98]. 
Hence, the pathophysiology of T2D is complex and involves dysfunctional regulation of 
metabolism in numerous tissues. 
Skeletal muscle regulation of glucose metabolism is disturbed in T2D due to insulin 
resistance. Insulin resistance in skeletal muscle is a primary defect in T2D disease 
progression [99], and is characterized by reduced insulin-stimulated glucose uptake and 
glycogen synthesis. Factors mediating insulin resistance in skeletal muscle include ectopic 
lipid deposition, increased local and systemic inflammation, glucotoxicity, and mitochondrial 
dysfunction [83]. Skeletal muscle insulin resistance is linked to reduced phosphorylation and 
activation of proteins involved in insulin signaling such as IRS1, PI3K [100], and AS160 
[101], defective insulin-stimulated GLUT4 translocation to the plasma membrane [102, 103], 
and reduced insulin-stimulated glucose transport [102, 104]. Although, identifying the 
molecular regulators responsible for these dysfunctions in skeletal muscle is still needed, 
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there is considerable evidence that skeletal muscle insulin resistance plays an important role 
in the etiology of disturbed glucose homeostasis in T2D. 
1.3.3 miRNA-regulation of glucose metabolism 
miRNAs have been implicated as regulators of T2D-related traits in several tissues including 
adipose, liver, pancreas, and skeletal muscle. In adipose tissue, miRNAs regulate 
inflammation in humans [105], and a recent publication indicates that adipose-derived 
circulating miRNAs in exosomes of mice can regulate gene expression in other tissues such 
as the liver indicating that dysregulated adipose tissue miRNA expression directly could 
impact whole-body metabolism [106]. A miRNA enriched in hepatocytes, miR-122, regulates 
cholesterol metabolism and is important for anti-inflammatory functions within the liver 
[107, 108]. Inhibition of the miR-103/107-family in adipose and liver improves insulin 
sensitivity and glucose homeostasis in obese animal models [109]. Pancreatic β-cells are also 
affected by miRNA-dependent regulation as evidenced by the involvement of miR-375, a 
miRNA enriched in β-cells, in β-cell proliferation and, thus, regulation of insulin secretion 
[110]. The examples reported herein simply highlight the important regulatory roles of 
miRNAs in glucose homeostasis. 
In skeletal muscle, the expression profile of individual genes in T2D subjects is not 
markedly different than non-diabetic subjects [111, 112]. However, analysis of functionally 
related networks reveals that genes related to mitochondrial function are dysregulated in 
diabetic skeletal muscle [112]. Thus, T2D skeletal muscle dysfunction is characterized by 
alterations in transcription, indicating a potential role for miRNA-dependent regulation. 
Several miRNAs have altered expression in skeletal muscle of insulin resistant mouse models 
[113-115] and in humans with T2D [111]. Expression of miRNAs is also altered in skeletal 
muscle following a hyperinsulinemic-euglycemic clamp [116]. Accordingly, skeletal muscle 
miRNA expression is sensitive to endocrine and metabolic regulation. The myomiRs miR-
133a and miR-206 are decreased in skeletal muscle from T2D patients [111]. Interestingly, a 
recent report highlights the role of miR-133a, in combination with miR-1, in the regulation of 
genes involved in mitochondrial function [67]. Although there is a clear role for miRNA-
mediated regulation of metabolism, only a few miRNAs have been studied in vitro or in vivo 
in relation to insulin resistance and diabetes in skeletal muscle. 
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1.4 EXERCISE 
1.4.1 Health benefits of exercise training 
The health benefits of physical activity and regular exercise training include improved bone 
strength, reduced adiposity, improved glucose homeostasis, decreased blood pressure, 
increased cardiac output, as well as a reduced risk to develop depression and T2D [117]. 
Overall, a lack of physical activity is strongly associated with reduced health-related quality 
of life and shortens life expectancy by 0.4–4.2 years [118, 119]. These findings are not 
unexpected with regard to theories of human evolution indicating that the genus Homo is well 
adapted for endurance-related activities [120]. Thus, the reduced physical activity and 
increased sedentary time observed in modern societies could be considered inconsistent with 
how humans have evolved. Nevertheless, evolutionary theories also predict that while 
humans are adapted to perform endurance-related activities, we are also prone to avoid 
unnecessary exertion [120], possibly explaining why so few individuals meet exercise 
guidelines and comply with recommendations of increased physical activity [121]. 
Direct or indirect effects of endurance exercise training are observed in several tissues 
including adipose [122], liver [123], pancreas [124], and the contracting skeletal muscle. 
Physical activity reduces adiposity in obese individuals [125]. Since obesity is a risk factor 
for developing insulin resistance and T2D [88], physical activity and endurance training also 
reduce the risk of acquiring these conditions [126]. Nevertheless, not all of the positive 
effects of endurance exercise training in obese individuals are connected to weight loss, as 
glycemic control is improved before changes in body weight are achieved [127]. Physical 
activity, defined as at least 150 min per week of combined resistance and endurance exercise, 
improves glycemic control in individuals with T2D [128], and is therefore a recommended 
intervention for patients [129]. Exercise in combination with diet interventions can be as 
effective as pharmacological interventions in the prevention of T2D development [130]. 
Additionally, endurance exercise affects glucose homeostasis in healthy individuals. Healthy 
young volunteers exhibit exercise-induced improvements in glucose tolerance and fasting 
glucose levels [131, 132], while only ten days of exercise abstention worsens glucose 
tolerance and insulin sensitivity in master athletes [133]. Thus, exercise training is a potent 
tool to maintain normal glucose homeostasis and prevent the development of insulin 
resistance and T2D. 
1.4.2 Exercise-induced alteration in skeletal muscle function 
Skeletal muscle is a plastic tissue that is responsive to environmental cues and can readily 
remodel to adapt to increased demands of repeated skeletal muscle activity. With repeated 
bouts of contraction with exercise, alterations in substrate metabolism, mechanical stress, 
calcium flux, and redox balance will change the activities of multiple signaling pathways 
[134]. These signaling pathways ultimately alter gene expression via transcription factors and 
epigenetic mechanisms. Changes in the skeletal muscle transcriptome occurs in response to a 
single bout of endurance exercise [135], as well as training [136, 137]. Specifically, genes 
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related to mitochondrial biogenesis and oxidative metabolism are altered [137], as well as 
genes regulating the extracellular matrix composition [138, 139], vascularization [140], and 
glucose metabolism [136]. Thus, several of the defects associated with skeletal muscle 
function in T2D are reversed by exercise and exercise training. 
Improved glucose uptake and insulin sensitivity are observed in skeletal muscle 
following exercise. Contraction of the working skeletal muscle promotes glucose uptake 
through an insulin-independent mechanism [141-143]. This uptake is mediated by 
phosphorylation of TBC1 Domain Family Member 1 (TBC1D1) [144], a functionally related 
protein to TBC1D4 (see Figure 2 for an overview of contraction-induced glucose uptake). 
Nevertheless, exercise improves skeletal muscle insulin sensitivity, as evidenced by the fact 
that endurance exercise training improves insulin-stimulated glucose uptake [145]. Improved 
insulin-stimulated glucose uptake following exercise is associated with increased insulin-
mediated phosphorylation of AS160 [146], and increased protein abundance of GLUT4 
following endurance exercise and training [136, 147]. These modifications are also observed 
in skeletal muscle of T2D patients following exercise training [148, 149]. Thereby, endurance 
training is a potent inducer of insulin-stimulated signaling and glucose transport in skeletal 
muscle of people with T2D. 
Endurance exercise training-associated improvements in skeletal muscle insulin 
sensitivity have several mechanistic explanations. For example, the peroxisome proliferator-
activated receptor gamma coactivator 1-alpha (PGC1α) is a transcriptional coactivator with 
increased expression upon endurance training [150]. PGC1α is considered a master regulator 
orchestrating transcriptional networks that alter mitochondrial function and lipid oxidation 
[151]. Metabolic flexibility, defined as the ability of an organism or tissue to adapt fuel 
oxidation to fuel availability, is disturbed in T2D [152] and is associated with mitochondrial 
dysfunction, as well as a reduced capacity to oxidize lipids in the fasted state [153, 154]. 
Improvements in fasting lipid oxidation is a strong predictor for enhanced insulin sensitivity 
[155]. Furthermore, skeletal muscle oxidative capacity is a predictor of whole-body insulin 
sensitivity [156]. Skeletal muscle has an increased reliance on lipids as an energy source 
following endurance training [157]. This increased skeletal muscle oxidative capacity is 
associated with improvements in insulin sensitivity in T2D after endurance exercise training. 
PGC1α is a candidate regulating these alterations, although further mechanistic insights into 
the specific molecular and cellular events by which exercise enhances insulin sensitivity may 
uncover novel therapeutic entry points for insulin resistance and diabetes. 
1.4.3 miRNA-regulation during exercise training 
Acute endurance exercise and regular exercise training alter the expression of miRNAs and 
genes involved in miRNA processing. One bout of endurance exercise increases the mRNA 
abundance of Drosha, Exportin-5, and Dicer transcripts in human skeletal muscle [158]. 
Endurance exercise also increases the expression of several myomiR members, including 
miR-1 and miR-133a [158, 159]. Conversely, endurance training has the opposite effect on 
myomiR expression, as miR-1, miR-133a/b, and miR-206 are decreased following 12 weeks 
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of endurance training [159]. Several of these miRNA species, including miR-1 and miR-
133a, are also downregulated following six weeks of endurance training [137]. Resistance 
training has not been reported to be associated with altered myomiR expression [160]. 
Furthermore, skeletal muscle disuse induced by bed rest is associated with decreases in 
myomiR expression [161, 162]. Thus, the divergent modulation of myomiRs expression in 
response to muscle activity may be explained by remodeling processes that differ depending 
on the type and duration of stimuli. 
Most studies that have determined miRNA expression following endurance exercise 
have focused on either myomiR expression or pre-selected candidates. Several non-myomiR 
miRNAs are altered following six weeks of endurance training [137], where more miRNAs 
are downregulated compared to upregulated (14 and 7, respectively). As there was 
enrichment for miRNA target genes in gene ontologies related to metabolism, miRNAs are 
suggested to regulate part of the exercise-induced alterations in skeletal muscle metabolism 
[137]. Future mechanistic studies are required to provide direct evidence for miRNA-
mediated regulation of the endurance exercise-induced adaptive response of human skeletal 
muscle.  
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2 AIMS 
Proper post-transcriptional control is essential for the regulation of multiple cellular functions 
including proliferation, differentiation, and energy metabolism. How miRNAs regulate 
human skeletal muscle function is incompletely understood. To address this, the overarching 
aim of this thesis was to determine roles for miRNAs in the regulation of skeletal muscle 
development and function. Specifically, the sub aims were: 
 
• To determine the expression of miRNAs during the differentiation of primary human 
skeletal muscle cells. In conjunction with this, the functional effects of differentially 
expressed miRNAs on target gene expression were characterized during the 
differentiation process. 
 
• To determine the expression of the miR-29 family members in skeletal muscle from 
glucose tolerant individuals as compared to type 2 diabetic patients. The thesis also 
aimed to charactherize the roles of these miRNAs in regulation of human skeletal 
muscle metabolism and insulin sensitivity. 
 
• To characterize the miRNA expression in human skeletal muscle in response to 
endurance exercise training. Aims of the thesis also included the investigation of the 
roles played by differentially expressed miRNAs on functions associated with 
training-induced alterations, including insulin sensitivity, as well as glucose and lipid 
metabolism. 
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3 EXPERIMENTAL PROCEDURES AND 
METHODOLOGICAL CONSIDERATIONS 
Reported here are selected methods utilized for data acquisition in studies presented in this 
thesis. The order in which the methods are presented provides an overview of the workflow 
employed in these studies. Biological material was required in order to answer the scientific 
questions that this thesis aimed to address. The cohorts representing different conditions (i.e., 
skeletal muscle differentiation, diabetes, or endurance exercise training) are presented first. 
Thereafter, a description of techniques to determine expression of miRNAs is provided. 
Differentially regulated miRNAs were studied and the effects of these miRNAs on post-
transcriptional regulation and/or metabolism were assessed in skeletal muscle cells or in 
mouse skeletal muscle tissue. Lastly, the effects of the specific miRNAs studied were linked 
to predicted or validated target genes using different approaches. 
A detailed description of methods used in the thesis is provided in the individual 
papers. The goal of this section, however, is to discuss advantages and disadvantages of the 
techniques and why certain methods were chosen for data acquisition. 
3.1 SKELETAL MUSCLE CELL CULTURES 
Satellite cells were extracted by enzymatic dissociation from human skeletal muscle biopsies 
or whole mouse skeletal muscle [163, 164]. Isolated cells, growing as proliferating 
myoblasts, were cultured in CO2-ventilated, humidified incubators at 37°C with liquid media 
containing all necessary nutrients for growth. The cells originated from skeletal muscle 
biopsies taken from healthy volunteers and all subjects provided written informed consent. 
The ethical committee at Karolinska Institutet approved the study protocols and all protocols 
followed the principles of the Declaration of Helsinki. 
Skeletal muscle myoblasts differentiate into multinucleated myotubes that resemble 
mature skeletal muscle in expression of muscle-enriched miRNAs and genes. Nevertheless, 
results obtained from in vitro models cannot simply be used to draw direct conclusion to 
clinical practice. Using primary human skeletal muscle cells from several donors improves 
the ability to translate results from in vitro studies to human physiology since studies are 
performed with a diversity of genetic backgrounds. Thus, primary human skeletal muscle 
cells provide an invaluable research tool in the study of skeletal muscle development, 
differentiation, and metabolism. In Study I, primary human skeletal muscle cells were 
utilized for determination of miRNA and gene expression during the differentiation process. 
RNA was collected at 48-hour intervals and expression of miRNAs and genes was assessed.  
Immortalized skeletal muscle cell lines of human (LHCN-M2), rat (L6), and mouse 
(C2C12) divide rapidly. Thus, they can be used to quickly collect large amounts of data. 
Furthermore, these cells are easily accessible for most laboratories and thus provide 
opportunities for investigators to validate results published from other groups. Nevertheless, 
compared to primary human skeletal muscle cells, translatability of results from these models 
is limited since these cells are genetically homogeneous and some of these models have 
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perturbed insulin signaling and glucose metabolism. Representative images of proliferative 
and fully differentiated skeletal muscle cell models used in this thesis are shown in Figure 3. 
3.1.1 Functional experiments in cells 
Many of the results in this thesis were produced by studying the effects of selected miRNAs 
in skeletal muscle cells cultured in vitro. Modulation of expression of miRNAs, genes, and 
proteins can be achieved by several methodologies. Short RNA molecules such as miRNA 
precursors or inhibitors or short interfering RNA (siRNA) can be introduced into skeletal 
muscle cells by transfection, including liposome-based transfection. Other methods of 
altering expression can be through DNA-based delivery methods (e.g., transfection, 
electroporation, or transduction), although large DNA plasmids are not easily introduced into 
primary skeletal muscle cells. 
For the studies reported in this thesis, cells of different tissue and species origin were 
transfected with miRNA precursors or inhibitors. In Study I, miRNA precursors for miR-30b 
and -30c were transfected into human skeletal muscle cells to determine the effects on gene 
expression of miR-30b/c predicted targets. Additionally, luciferase assays were used in 
human embryonic kidney cells (HEK293) transfected with miR-30b or -30c precursors to 
determine if the miRNAs could bind directly to the 3’UTRs of predicted target genes 
RASAL2 and WNT5A. In Study II, miR-29a and -29c precursors or inhibitors were 
transfected into human skeletal muscle cells to determine the effects on glucose and lipid 
metabolism, expression of genes, and protein signaling. In Study III, endurance exercise 
training-regulated miR-19b-3p and miR-107 were overexpressed in primary skeletal muscle 
cells from humans and mice, as well as in C2C12 cells, through transfection of miRNA 
precursors. Inhibitors of miR-19b-3p and miR-107 were also transfected into human skeletal 
muscle cells to determine endogenous effects of these miRNAs. Additionally, siRNA 
targeting either MAPK6 or RNF11 were transfected into human skeletal muscle cells. 
Following transfection of miRNA precursors or inhibitions, or siRNAs, substrate metabolism 
and insulin sensitivity were studied in addition to gene expression and protein signaling. 
Primary mouse skeletal muscle cells and C2C12 cells were used to elucidate conservation of 
miRNA functionality and target recognition between species. 
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Figure 3. Overview of cell culture models utilized in this thesis. Representative immunocytochemistry images of C2C12 skeletal muscle cells and primary mouse and 
human skeletal muscle cells before induction of differentiation (Proliferative myoblasts) and following differentiation (Differentiated myotubes). Fixated cells were 
incubated with primary antibodies targeting myosin heavy chain 1 and 2 (MYH1/2) and Desmin prior to being incubated with fluorophore-conjugated secondary antibodies 
directed against the primary antibodies. Nuclei were stained using 4’,6-diamidino-2-phenylindole (DAPI). Desmin and DAPI staining is merged (Merge). 
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3.2 COHORT FOR STUDIES OF miRNA EXPRESSION IN TYPE 2 DIABETIC 
PATIENTS 
T2D is characterized by disturbed glucose homeostasis resulting in increased fed and fasted 
blood glucose levels. In Study II, a cohort of individuals with normal glucose tolerance 
(NGT) or T2D was used to determining skeletal muscle expression of miR-29 family 
members. The clinical characteristics of these individuals are reported in Table 2. The cohort 
consisted of male volunteers who were not insulin treated. The cohort was matched for age, 
weight, and BMI. Skeletal muscle biopsies from vastus lateralis was obtained under local 
anesthesia following an overnight fast. The ethical committee at Karolinska Institutet 
approved the study protocols that adhered to the principles of the Declaration of Helsinki. All 
subjects provided written informed consent. 
3.3 COHORT FOR STUDIES OF miRNA EXPRESSION FOLLOWING 
ENDURANCE EXERCISE TRAINING 
In Study III, miRNA expression was assessed in skeletal muscle biopsies from young and 
sedentary, but otherwise healthy, men. Four biopsies were collected: before the start of the 
program, and after one day, ten days and fourteen days of an endurance exercise-training 
program. This program consisted of supervised exercise for one hour per day on an 
electronically braked cycle ergometer at 80% of pre-determined peak oxygen uptake 
(VO2peak) for 14 consecutive days. Biopsies from the vastus lateralis skeletal muscle were 
taken under local anesthesia in the morning following an overnight fast. All biopsies were 
taken at least 16 hours after completion of the last exercise bout. All participants provided 
written informed consent and the research ethical committee at Dublin City University 
approved the study protocols that were conducted according to the Declaration of Helsinki. 
The anthropometric characteristics are given in Table 2. 
3.4 METHODS TO DETERMINE miRNA AND GENE EXPRESSION 
Although the DNA sequence is nearly identical across cell types in an organism, the 
expression of RNA molecules is highly variable between cell populations. There are many 
different methods to assess the expression of RNA molecules in biological material. When 
determining the expression of single miRNAs or mRNAs, reverse transcription-quantitative 
PCR (RT-qPCR) with specific DNA primers is often the preferred method. There are also 
methods available to determine expression of all RNAs in a biological sample at once. This is 
achieved with gene arrays or by RNA sequencing (RNA-seq), which generate transcriptomic 
expression profiles of multiple RNAs simultaneously. Gene arrays are relatively inexpensive 
and easy to process, although RNA-seq is becoming less expensive and easier to analyze. 
One advantage of RNA-seq over gene arrays is that detection is limited to transcripts existing 
in the sample, whereas gene arrays give signal intensities for all probes on the chip (even 
though a transcript might not be expressed). Another advantage of RNA-seq is that it does not 
require prior knowledge about what RNA sequences that can be detected. Transcriptomic 
methods often suffer from lower sensitivity and specificity compared to univariate analysis 
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methods, making validation of data generated by transcriptomic approaches critical. 
Detection and determination of miRNA abundance is complicated by their lack of a polyA-
tail and their short length, complicating sequencing-library preparation and amplification by 
standard RT-qPCR methods. 
Table 2. Anthropometric data of human cohorts studied in this thesis. 
 
 STUDY II STUDY III 
NGT T2D Pre-training Post-training 
n 
(male/female) 10 (10/0) 12 (12/0) 8 (8/0) - 
Age 
(years) 59.0 ± 5.3 62.1 ± 4.4 22.9 ± 6.5 - 
Height 
(cm) 178.7 ± 7.8 175.4 ± 4.1 178.8 ± 7.6 - 
Weight 
(kg) 92.4 ± 7.9 97.3 ± 12.9 75.3 ± 8.4 - 
BMI 
(kg/m2) 28.9 ± 1.9 31.6 ± 3.6 23.6 ± 2.6 - 
Fasting glucose 
(mmol/L) 5.4 ± 0.3 8.6 ± 1.7 Not determined 
2-hour glucose 
(mmol/L) 6.7 ± 1.0 16.3 ± 3.3 ¤ Not determined 
Fasting insulin 
(pmol/L) 61.2 ± 21.3 76.8 ± 33.7 ¤ Not determined 
HbA1c 
(%) 4.6 ± 0.2 6.0 ± 0.9 ¤ Not determined 
VO2peak 
(L/min) 2.6 ± 0.4 2.2 ± 0.6 2.8 ± 0.4 3.3 ± 0.3 ** 
VO2peak 
(ml/min/kg) 28.0 ± 5.8 23.6 ± 7.6 38.3 ± 10.1 44.6 ± 8.4 *** 
Triglycerides 
(mmol/L) 1.6 ± 0.6 1.4 ± 0.6 Not determined 
Cholesterol 
(mmol/L) 5.8 ± 0.8 4.2 ± 0.6 ¤ Not determined 
HDL 
(mmol/L) 1.3 ± 0.5 1.3 ± 0.4 Not determined 
LDL 
(mmol/L) 3.8 ± 0.7 2.3 ± 0.6 ¤ Not determined 
 
VO2peak: Peak oxygen consumption. HDL: High-density lipoprotein. LDL: Low-density lipoprotein. 
Data are mean ± SD. ¤p<0.001 comparing NGT to T2D by Student’s t-test in Study II. **p<0.01 and 
***p<0.001 comparing pre-training to post-training by paired Student’s t-test in Study III. 
 
In this thesis, three different methods for determination of RNA expression have been 
utilized: miRNA and gene expression arrays (Affymetrix), short RNA sequencing, and RT-
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qPCR. In Study I, miRNA expression was determined in primary human skeletal muscle 
cells by miRNA arrays at 48-hour intervals during differentiation of myoblasts into 
multinucleated myotubes. Gene expression was also determined by gene arrays before 
inducing differentiation and after four and ten days of differentiation. In Study II, an 
examination of the literature identified the miRNA-29 family members as candidates for 
further study, thus no hypothesis generating transcriptome analysis was performed. For 
Study III, alterations in miRNA expression in human skeletal muscle following a 14-day 
consecutive endurance exercise-training program was determined by short RNA sequencing. 
In this method, short RNAs are purified by miRNA-specific extractions and polyacrylamide 
gel electrophoresis (PAGE). To identify target genes of miRNAs, gene expression was 
determined with gene arrays in human skeletal muscle cells following overexpression of 
either miR-19b-3p or miR-107. In Study I-III, RT-qPCR was used for validation and 
quantification of gene and miRNA expression. 
Other potential methods to assess RNA abundance are Northern Blot and in situ 
hybridization. Northern blot is a semi quantitative methodology that requires a large amount 
of input material. Nevertheless, the method has several advantages including validation of 
correct size of the RNA molecule being assessed and high specificity of probes. In situ 
hybridization is a method to determine presence and localization of RNAs in tissues. 
However, this methodology can be time consuming in terms of optimization. Neither of these 
methods was used for data generation for studies reported in this thesis. 
3.5 TRANSLATION OF RODENT RESEARCH TO HUMAN PHYSIOLOGY 
Since results generated from in vitro models, such as cell cultures, cannot be directly 
translated into human physiology, other models are warranted. To generate results from an in 
vivo setting, biologists often turn to rodents. Some advantages of murine research include the 
facts that mice are mammals, there are several mouse models for human diseases, the mouse 
genome is sequenced, and mice have a fast reproduction time. All work with animals 
presented in this thesis was approved by the Regional Animal Ethics Committee (Stockholm, 
Sweden). Animals were housed on a 12 hour light/12 hour dark cycle and received ad libitum 
access to water and standard rodent chow. 
3.5.1 Functional experiments in rodents 
Animal models are frequently used in study of metabolic disease. Examples of animal models 
used for studies of metabolic disorders are genetic models (such as ob/ob and db/db mice) or 
animals with high fat diet-induced obesity and glucose intolerance [165]. In Study II, 
expression of the miR-29 family members was assessed in gastrocnemius skeletal muscle 
from wild type and ob/ob mice. The ob/ob mice develop severe obesity, hyperinsulinemia, 
and hyperglycemia due to lack of circulating leptin arising from a mutation in the gene 
coding for leptin [166]. Expression of miR-29 family members was also assessed in rat 
skeletal muscle of Wistar rats that were randomized to either a sedentary control group or an 
endurance swimming program. The swimming program consisted of two three-hour bouts of 
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swimming per day for five consecutive days and gastrocnemius skeletal muscle was collected 
16 hours after the last swimming bout. 
Expression of genes or miRNAs can be altered transiently in rodent skeletal muscle 
by electroporation of DNA vectors. Pre-treatment of tibialis anterior (TA) skeletal muscle for 
two hours with hyaluronidase (30 µl of 1 unit/µl) improves transfection efficiency while 
reducing muscle damage [167]. Thereafter, 30 µg of DNA vector was injected directly into 
the skeletal muscle tissue and electroporation was performed by delivering 220 V/cm as eight 
pulses of 20 ms using an electroporator. Flexor digitorum brevis (FDB) skeletal muscle were 
also pretreated with hyaluronidase and injected subcutaneously with 20 µg of DNA vector 
and thereafter electroporated. The contralateral respective skeletal muscles were 
electroporated with a control vector. TA or FDB skeletal muscles were collected one week 
after electroporation following a four-hour fast. In Study II and Study III, electroporation 
was used for overexpression of pri-miR-29a or pri-miR-29c, and pri-miR-19b-3p or pri-miR-
107, respectively, in TA skeletal muscle. In both studies, muscle tissue was used for 
assessment of miRNA-induced alteration in gene expression and protein abundance. In Study 
II, a modified glucose tolerance test was performed to assess glucose uptake into 
electroporated TA muscles. A bolus of glucose was administered by gavage, while 2-[3H]-
deoxy-D-glucose was given intraperitoneally to assess tissue-specific glucose uptake. In 
Study III, FDB skeletal muscle was electroporated with either miR-19b-3p or miR-107 
encoding DNA vectors. One week after electroporation, FDB skeletal muscles were carefully 
dissected out and subjected to contraction ex vivo followed by glucose transport assay to 
determine basal and contraction-induced glucose uptake.  
In Study III, expression of endurance exercise-regulated miRNAs was assessed in 
mouse skeletal muscle collected from wild-type animals following cardiac perfusion. Cardiac 
perfusion was performed to remove blood from tissues, thereby removing potential 
contaminating miRNAs from serum or various blood cells. Expression of endurance exercise 
training-induced miR-19b-3p and miR-107 was also determined in soleus and extensor 
digitorum longus (EDL) skeletal muscle. Soleus skeletal muscle is predominantly constituted 
of type I oxidative fibers and EDL is enriched with type II glycolytic fibers.  
3.6 IDENTIFICATION OF miRNA TARGETS 
Approximately 60% of all human protein-coding genes contains miRNA binding sites that 
are believed to be under selective pressure [26]. Identification of direct targets of a miRNA is 
therefore a challenging task. The dominant motif of a miRNA, its seed region, is used by 
different target identification algorithms (e.g., TargetScan [168] and mirSVR [169]) to 
predict direct targets of miRNAs. These algorithms often scan 3’UTRs for conserved 
complementary seeds, but all algorithms have their own models to determine predicted 
targets. Factors that are given different weight for the final results of such prediction 
algorithms include complementary binding outside of the seed, location within the 3’UTR, 
binding outside of the 3’UTR, strength of binding (8mer>7mer>6mer), secondary structure, 
and number of predicted binding sites in a gene [170]. Unfortunately prediction algorithms 
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produce many false positives [171], and target recognition can be improved using 
experimental data where the activity of a miRNA is altered. Since most mammalian miRNAs 
reduce mRNA abundance [25], determining mRNA abundance using gene arrays or RNA-
seq following miRNA inhibition or overexpression is a common approach to identify 
regulated targets. Proteomics analysis is also a useful tool for determination of miRNA-
induced changes in protein abundance, although current techniques are only able to detect a 
relatively small fraction of all proteins in a biological sample. In Study II, algorithms were 
used for identification of predicted targets of studied miRNAs, while in Study I and III a 
combination of transcriptome data with prediction algorithms was used to identify miRNA 
targets with altered expression. 
Biochemical approaches to infer direct regulation of target expression by miRNAs 
have been developed. High-throughput sequencing (HITS) of AGO-associated miRNAs and 
mRNAs can be performed following crosslinking and immunoprecipitation (CLIP) [172]. 
Several different methods for crosslinking of RNAs to AGO have been developed, as 
reviewed elsewhere [173]. Recently, AGO CLIP was employed following C2C12 
differentiation, providing novel data regarding skeletal muscle-enriched miRNAs and their 
endogenous targets during skeletal muscle development [174]. Luciferase assays are the ‘gold 
standard’ for validation of direct binding of a miRNA to a target’s 3’UTR. Using this 
technique, as employed in Study I, the predicted target genes 3’UTRs are cloned downstream 
of the luciferase gene. If the miRNA binds directly to the 3’UTR, luciferase expression is 
expected to be reduced following miRNA overexpression. 
Directly linking a miRNA-regulated target to cellular effects of that miRNA is 
challenging. miRNAs can regulate multiple genes, and thus cellular effects induced by a 
specific miRNA are difficult to tie to a single target gene. miRNA target protectors are tools 
developed for directly linking miRNA-induced effects on a single target [175]. These target 
protectors are RNA sequences directly complementary to the sequence where the 
miRNA:mRNA interaction occurs in the 3’UTR of the target gene. Thus, miRNA will be 
blocked from binding to the target gene, allowing the mRNA to be translated by the ribosome 
without miRNA interference. Recently, CRISPR-based methods to alter cellular DNA have 
revolutionized the field of DNA editing and are now cost-effective alternatives to other gene-
editing methods [176]. CRISPR can be utilized in numerous ways to study the effects of 
miRNAs on cellular function and target gene expression regulation. For example, miRNA 
binding sites in a target gene’s 3’UTR could be specifically edited and direct effects on 
phenotypic alterations induced by a miRNA could consequently be linked to that target gene. 
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4 RESULTS AND DISCUSSION 
4.1 STUDY I: ASSESSMENT OF miRNA EXPRESSION DURING HUMAN 
SKELETAL MUSCLE CELL DIFFERENTIATION 
Determination of altered expression of miRNAs and genes can provide information on 
skeletal muscle development in healthy and diseased states. For example, the miRNA 
maturation machinery is needed for proper skeletal muscle miRNA biogenesis, regulation of 
muscle mass, and healing in response to injury [54, 55]. miRNAs enriched in muscle are also 
regulators of functional development and muscle remodeling [43, 66, 67]. The expression of 
five miRNAs is consistently dysregulated in ten different major human muscular disorders 
[177]. Moreover, in mice, miR-133 delays progression of Duchenne muscular dystrophy [66]. 
Given the apparent links between miRNA function and skeletal muscle development, an aim 
of this thesis was to determine miRNA expression in a human model of muscle 
differentiation. 
4.1.1 Numerous miRNAs are altered during human skeletal muscle cell 
differentiation 
Skeletal muscle precursor cells can readily differentiate in vitro into fused myotubes. This can 
be achieved by reducing growth factor concentrations in the culture media. In this study, 
human progenitor cells were isolated from skeletal muscle biopsies from healthy volunteers. 
Thereafter, RNA was collected from cells before the induction of differentiation and at 48-
hour intervals during ten days of differentiation. By using miRNA arrays, the expression of 
1,276 putative miRNAs was monitored during the differentiation process. Following 
exclusion of non-expressed miRNAs, 206 were detected in either proliferative or 
differentiated skeletal muscle cells of which 44 were altered during the differentiation process 
(Fig. 4A). When comparing expression profiles of differentiating cells at any time point 
during the differentiation process to proliferate cells, 103 miRNAs exhibited altered 
expression in at least one time point. In comparison, another study, using miRNA arrays that 
covered fewer miRNAs (365), identified altered expression of 60 miRNAs following 
differentiation of human skeletal muscle cells [71]. Out of the 103 miRNAs identified in 
Study I, about 1/3 had not been previously linked to myogenesis in human or mouse. The 
expression of ten altered miRNAs was validated by RT-qPCR, and eight of these have 
increased expression following differentiation, as highlighted by increased miR-1, miR-30b 
and -30c, and miR-206 expression (Fig. 4B). The largest relative fold changes upon 
differentiation were seen for canonical myomiRs, confirming results from several other 
studies [59, 60, 71]. Thus, 103 miRNAs with altered expression during human skeletal 
muscle cell differentiation were identified, including novel myogenesis-associated miRNAs. 
4.1.2 Identification of biologically relevant targets of altered miRNAs 
There are several potential approaches to identify targets of miRNAs. As mammalian 
miRNAs predominantly alter mRNA levels of target genes [25], gene arrays were utilized 
prior to and following ten days of differentiation to identify candidate targets of the miRNAs.  
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Figure 4. miRNA expression during skeletal muscle cell differentiation. Primary human skeletal 
muscle cells were cultured and RNA harvested during proliferation and at 48h intervals during 
differentiation. A) Heatmap of 44 miRNAs altered during the time course of differentiation. B) RT-
qPCR validation of selected miRNAs focused upon in this thesis. Data are mean ± SEM, n = 6. # p < 
0.05 as determined by repeated-measures ANOVA. *p < 0.05 by Dunnett’s post hoc test. 
Unfortunately, due to limited RNA amounts, expression was only determined in three out of 
the six subjects initially used for determination of miRNA expression. Nevertheless, 949 
genes with altered expression were identified following ten days of differentiation. Using a 
bioinformatic tool (Ingenuity Pathway Analysis) to overlap altered miRNAs with predicted 
target genes that were differentially expressed during differentiation, predicted networks with 
miRNA-centered regulatory nodes were assembled. For example, several downregulated 
genes predicted as targets of miR-1/206 (which share similar seed regions) and miR-30b/c are 
highlighted (Fig. 5A-B). Using this approach known and novel myogenesis-associated 
predicted targets of miR-1 and miR-206 with altered expression during differentiation were 
identified (Fig. 5A). 
 
Figure 5. miRNA-centered regulatory networks of human skeletal muscle differentiation. 
Expression of differentially regulated miRNAs and mRNAs were determined by transcriptomic 
analysis of cultured primary human skeletal muscle cells. miRNAs (central node) are connected to 
reciprocally regulated predicted target genes (peripheral nodes) by edges. Predicted regulatory 
networks of A) miR-1 and miR-206, and B) miR-30b and miR-30c. 
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An example of previously validated miR-1 and miR-206 target is PAX7 [61]. Novel target 
genes that are linked to satellite cell senescence, skeletal muscle proliferation, differentiation, 
or regeneration include HEYL [178], PFKFB3 [179], and PHLDA1 [180]. The relative 
importance of these genes for miR-1/206-regulated processes during skeletal muscle cell 
differentiation requires further studies. 
4.1.3 miR-30b and miR-30c-regulated genes during human skeletal muscle 
cell differentiation 
The miR-30b and miR-30c-centered gene regulatory network (Fig. 5B) identified 76 
predicted target genes with decreased expression upon skeletal muscle cell differentiation. 
Among these targets, several known transcriptional regulators of cell cycle progression, 
including E2F7 [181], and skeletal muscle maturation and development, such as PRDM1 
[182] and SNAI1 [183] were identified. These findings are interesting in regards to the finding 
that inhibition of miR-30 abrogates differentiation in C2C12 skeletal muscle cells [74]. 
Further investigation is needed to clarify whether these 76 reciprocally regulated and 
predicted target genes are involved in the regulatory role of miR-30 during skeletal muscle 
differentiation. 
The roles of miR-30b and miR-30c in the regulation of selected candidate genes from 
the miRNA-centered network were further investigated. Correlation analysis of upstream 
miRNAs to downstream target genes was performed and 14 out of the 76 predicted target 
genes were negatively correlated to miR-30b or miR-30c expression during differentiation (p-
values were < 0.05 after Benjamini-Hochberg post hoc correction). Among these 14 genes, 
RASAL2 and WNT5A showed strong reciprocal expression levels to miR-30b (Fig. 6A-B) and 
miR-30c (Fig. 6C-D). When miR-30b or miR-30c was overexpressed in human skeletal 
muscle cells, the mRNA abundance of RASAL2 and WNT5A decreased (Fig. 6E). To 
determine if RASAL2 and WNT5A are direct targets of miR-30b or miR-30c, luciferase 
reporter plasmids were constructed (Fig. 6F). When these constructs were introduced into 
HEK293 cells that were transfected with either a negative control miRNA precursor or 
precursors for miR-30b or miR-30c, only RASAL2 was identified as a direct target of these 
miRNAs (Fig. 6G-H). These findings indicate that, while miR-30 members directly target 
RASAL2, reductions in WNT5A expression following miR-30 overexpression is likely 
achieved through either indirect effects of miR-30 or miR-30 interaction with an unidentified 
miR-30 binding sequence within the WNT5A transcript. RASAL2 is a Ras-specific GTPase-
activating protein [184], and has been linked to both promote and inhibit proliferation in 
different models [185, 186]. However, the effects of RASAL2 on skeletal muscle cell 
proliferation and differentiation remains to be elucidated. 
In conclusion, through integration of simultaneous miRNA and mRNA expression 
data miRNA-centred regulatory networks of gene expression during differentiation of human 
skeletal muscle cells were identified. 
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Figure 6. miR-30b and miR-30c are regulators of RASAL2 expression in human skeletal muscle 
cells. Primary human skeletal muscle cells were cultured and expression of differentially regulated 
miRNAs and mRNAs was determined by transcriptomic analysis. A-D) Expression of miR-30b (A-B) 
and miR-30c (C-D) was correlated (Pearson’s correlation) to the expression of predicted target genes 
RASAL2 (A and C) and WNT5A (B and D) during the differentiation process (n = 9). E) Gene 
expression of RASAL2 and WNT5A following overexpression of miR-30b or miR-30c was compared 
to transfection with a negative control (NC) in human skeletal muscle cells (n = 3). F) Constructs used 
for luciferase assays. G) Luciferase activity in HEK293 cells overexpressing the RASAL2 constructs 
shown in F following transfection with negative control (NC), miR-30b, or miR-30c (n = 6). H) 
Luciferase activity in HEK293 cells overexpressing the WNT5A constructs shown in F following 
transfection with negative control (NC), miR-30b, or miR-30c (n = 6). Data are mean ± SEM. *p < 
0.05 and **p < 0.01 as determined by paired Student’s t-test. 
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4.2 STUDY II: EFFECTS OF miR-29 FAMILY MEMBERS ON GLUCOSE AND 
LIPID METABOLISM IN SKELETAL MUSCLE 
miRNAs are potent regulators of insulin action in peripheral tissues including liver and 
adipose [109]. miRNAs have been implicated as regulators of skeletal muscle protein 
abundance in insulin resistant states, such as in T2D [111]. A meta-analysis of miRNA 
expression in insulin-responsive tissues identified several dysregulated miRNAs in conditions 
associated with insulin resistance in animal models and humans [187]. miR-29 family 
members were identified, and miR-29a was the most frequently reported upregulated 
miRNA. The miR-29 family members consist of three miRNAs: miR-29a, miR-29b, and 
miR-29c. Increased miR-29 expression was initially identified in skeletal muscle of rats that 
spontaneously develop insulin resistance and diabetes [113, 188]. However, expression of 
miR-29 members had not been determined in skeletal muscle of humans with insulin 
resistance. To address this, the expression of these miRNAs in human skeletal muscle from 
NGT controls and T2D patients was catalogued and the role of these miRNAs in metabolism 
was determined. 
4.2.1 miR-29a and miR-29c are increased in skeletal muscle from individuals 
with type 2 diabetes 
To determine the expression of miR-29 members in diabetic skeletal muscle, RNA was 
extracted from skeletal muscle biopsies from a cohort of control subjects with NGT and T2D 
patients (anthropometric data in Table 2). The expression of miR-29a and miR-29c was 
found to be increased in skeletal muscle from T2D patients, while miR-29b expression was 
not different between the T2D and NGT cohorts (Fig. 7A-C). These results corroborate 
previous findings of dysregulated miR-29 expression in insulin resistant tissues [187]. 
Additionally, miR-29 expression has been reported to be increased in skeletal muscle of a 
separate cohort of T2D patients compared to obese controls [189]. Disturbed lipid 
metabolism is a well-characterized defect in insulin resistant skeletal muscle [112, 153, 154]. 
Therefore, to elucidate the effects of lipid overload on miR-29 expression, human myotubes 
were exposed to palmitate and miR-29 expression was measured following 24 or 96 hours of 
treatment. Palmitate exposure of myotubes for 96 hours increased expression of miR-29a and 
miR-29c, reproducing the effects of palmitate on miR-29a expression reported in rat L6 cell 
cultures [190]. Thus, dysregulated expression of miR-29a and miR-29c in skeletal muscle 
from T2D patients could be linked to disturbed lipid metabolism. Since mitochondrial 
biogenesis and improved lipid metabolism is observed following endurance exercise training 
[157], the expression of miR-29 members was determined in human volunteers undergoing a 
14-day endurance training program (anthropometric data in Table 2). This training program 
resulted in increased expression of several mitochondrial proteins [191]. While miR-29a and 
miR-29b expression was unaltered following endurance training (Fig. 7D-E), abundance of 
miR-29c was decreased in skeletal muscle (Fig. 7F). Thus, altered miR-29c expression 
following endurance training and in T2D could be involved in regulation of skeletal muscle 
oxidative capacity.  
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Figure 7. Expression of miR-29 members in skeletal muscle of T2D patients and in healthy 
volunteers following 14 days of endurance exercise training. Expression of miR-29 members was 
determined by RT-qPCR in skeletal muscle from A-C) healthy volunteers with normal glucose 
tolerance (NGT) and type 2 diabetes patients (T2D) (n = 10–12). D-F) Healthy volunteers before 
(Baseline) and after completion of 14 consecutive days of endurance exercise training (Trained) (n = 
8). Data are mean ± SEM. *p < 0.05 as determined by paired or non-paired Student’s t-test. 
4.2.2 miR-29a and miR-29c are regulators of glucose metabolism in skeletal 
muscle 
Following the identification of altered miR-29 expression in skeletal muscle with exercise 
training and T2D, the metabolic effects of miR-29 members were determined. 
Overexpression of miR-29a and miR-29c decreased glucose uptake and insulin-stimulated 
glycogen synthesis in human skeletal muscle cells (Fig. 8A-B). Glucose uptake and total 
glycogen levels were reduced by overexpression of miR-29a and miR-29c in intact skeletal 
muscle of mice (Fig. 8C-D). Additionally, inhibition of miR-29c in human skeletal muscle 
cells enhanced basal and insulin-stimulated glucose uptake. These data support previous 
findings of decreased glucose uptake in rodent cell lines following miR-29 overexpression 
[113, 190, 192]. Associated with the miR-29-induced reduction in insulin responsiveness was 
reduced phosphorylation of AktSer473 and GSK3α/βSer21/9 in response to insulin stimulation of 
human skeletal muscle cells. Similarly, reduced phosphorylation of AktSer473 was also 
observed in mouse skeletal muscle overexpressing miR-29a and miR-29c following a two-
hour glucose tolerance test in mice. miR-29a and miR-29c were identified as regulators of 
lipid oxidation in human skeletal muscle cells. Overexpression of miR-29 members reduced 
palmitate oxidation, while inhibition of these miRNAs improved the cellular capacity to 
oxidize lipids. Thus, miR-29 members are potent and endogenous regulators of glucose and 
lipid metabolism and insulin responsiveness in skeletal muscle.  
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Figure 8. Overexpression of miR-29 members in skeletal muscle reduce insulin-responsive 
glucose metabolism. miR-29a, miR-29c, or a negative control (NC) was overexpressed in cultured 
human myotubes. Basal and insulin-stimulated (120 nM) A) glucose uptake and B) glucose 
incorporation into glycogen was assessed (n = 5). Intact tibialis anterior skeletal muscles of mice were 
electroporated with plasmids encoding either miR-29a, miR-29c, or a control (Ctrl) sequence. One 
week thereafter C) glucose uptake and D) total glycogen in skeletal muscle was assessed following a 
two-hour glucose tolerance test (n = 10). Data are mean ± SEM. # miRNA effect; ¤ insulin effect; ϕ 
interaction; determined by 2-way ANOVA.*p < 0.05 as determined by paired Student’s t-test or 
Bonferroni post hoc testing. 
4.2.3 Linking miR-29-induced metabolic alterations to regulation of gene 
expression 
To identify miR-29-targets that could explain the metabolic effects following overexpression 
or inhibition in skeletal muscle, conserved predicted miR-29-target genes implicated in 
insulin signaling and glucose metabolism were identified. The putative miR-29 targets IRS1, 
PIK3R3, and AKT2 were decreased following miR-29a and miR-29c overexpression (Fig. 
9A). Additionally, miR-29 also reduced expression of non-predicted target genes involved in 
regulation of glucose metabolism, such as hexokinase 2 (HK2) (Fig. 9A). These genes were 
also decreased in mouse skeletal muscle following overexpression of either miR-29a or miR-
29c, with miR-29c being more potent to regulate target gene expression in vivo. Additionally, 
miR-29 regulates endogenous expression of PGC1α and PDK4, genes controlling 
mitochondrial biogenesis and the cellular ability to switch between glucose or lipid energy 
sources, respectively. PDK4 is a predicted target (TargetScan) and PGC1α is a luciferase 
validated target of miR-29 members [193]. Thus, miR-29 family members control the 
expression of several regulators of skeletal muscle glucose and lipid metabolism. 
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Figure 9. miR-29 overexpression alters several genes involved in glucose metabolism. miR-29a, 
miR-29c, or a negative control (NC) was overexpressed in cultured human myotubes. A) Expression 
levels of putative targets and genes important for glucose metabolism were determined by RT-qPCR 
(n = 6), and B) hexokinase activity was assessed (n = 10). C) Expression of HK2 in healthy volunteers 
with normal glucose tolerance (NGT) or type 2 diabetes patients (T2D) (n = 10–12). D-E) Spearman 
correlation of D) miR-29a expression and E) miR-29c expression to expression of HK2 in NGT and 
T2D subjects (n = 10–12). Data are mean ± SEM. *p < 0.05 as determined by paired Student’s t-test. 
HK2 is a rate-limiting kinase in glycolysis given that it phosphorylates glucose to 
glucose-6-phosphate and thereby traps glucose metabolites in the cell. HK2 expression was 
reduced following miR-29 overexpression (Fig. 9A) and increased following inhibition. 
Consequently, human skeletal muscle cells overexpressing miR-29a or -29c exhibited 
reduced hexokinase activity (Fig. 9B). Inhibition of miR-29a increased hexokinase activity, 
while a trend was observed for miR-29c inhibition in cells, although no effect on hexokinase 
activity was found by miR-29 members in mouse skeletal muscle (data not shown). 
 33 
 
Previously unpublished data show a trend for decreased HK2 expression skeletal muscle from 
T2D patients (Fig. 9C). In a larger cohort of NGT and T2D individuals HK2 mRNA 
abundance is significantly decreased in skeletal muscle of T2D patients [194]. Correlation 
analysis of HK2 expression to miR-29a expression was not significant in skeletal muscle of 
NGT and T2D individuals (Fig. 9D). However, there is a significant inverse relationship 
between HK2 and miR-29c expression (Fig. 9E). These findings indicate that miR-29c could 
influence HK2 expression in human skeletal muscle and the elevated levels of miR-29c may 
be partially responsible for decreased HK2 transcript abundance observed in the T2D patients 
[194]. Nevertheless, HK2 is not a target gene of miR-29 as there are no miR-29-binding sites 
in the HK2 transcript. Because miR-29a and -29c reduced expression of PIK3R3, a regulatory 
subunit of PI3K, and HK2 expression is regulated through PI3K-dependent mechanisms 
[195], a miR-29/PI3K-pathway could explain the reduced expression and activity of 
hexokinase following overexpression pf miR-29a or -29c. Interestingly, insulin-stimulated 
PI3K activity is negatively regulated in skeletal muscle of insulin resistant individuals [100, 
104]. Additionally, endurance exercise training increases insulin-stimulated PI3K activity 
[196]. Thus, in conditions where PI3K activity and HK2 expression are known to be 
differentially regulated, expression of miR-29 members was found to be inversely expressed. 
In conclusion, expression of miR-29 members is decreased in skeletal muscle of T2D 
patients. miR-29a and miR-29c regulates glucose and lipid metabolism through regulation of 
important mediators of glucose and lipid metabolism, including HK2 and PGC1α. 
Additionally, miR-29 family members directly regulate the expression of canonical genes 
involved in the insulin-signaling cascade.  
4.3 STUDY III: ENDURANCE EXERCISE TRAINING-REGULATED miRNAS 
POTENTIATE GLUCOSE METABOLISM AND INSULIN SINGALING IN 
SKELETAL MUSCLE 
Acute exercise and regular exercise training are effective strategies to improve whole-body 
glucose metabolism and insulin resistance [128, 131]. Skeletal muscle is a plastic tissue that 
can adapt to increased physical activity by increasing insulin sensitivity [197], remodeling its 
extracellular matrix [138], and increasing the abundance of proteins involved in glucose 
metabolism [136]. Epigenetic regulation is associated with exercise training-induced 
adaptations [198], including alterations of skeletal muscle miRNA expression [137]. Here the 
aim was to determine the human skeletal muscle miRNA expression profile following 14 
consecutive days of endurance exercise. In addition, the functional roles of training-
responsive miRNAs in the regulation of training-associated adaptive traits in skeletal muscle 
were determined. 
4.3.1 miRNA expression is altered in human skeletal muscle following 
endurance exercise training  
Eight healthy young men underwent an exercise training program consisting of 14 
consecutive days of endurance exercise for one hour per day at 80% VO2peak (anthropometric 
data in Table 2). Skeletal muscle biopsies were taken from vastus lateralis skeletal muscle 
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prior to exercise (baseline) and in the mornings following one, ten, and fourteen days of 
training. To identify miRNAs with altered expression following exercise training short RNA-
seq was performed on RNA collected from biopsies at baseline and after 14 days of training 
(n = 3). This approach identified 12 differentially regulated miRNAs following training. In 
comparison to a previous study, this analysis identified fewer miRNAs to be altered 
following exercise training in skeletal muscle (12 in this study versus 21 in [137]). The 
duration of exercise training (2 versus 6 weeks) and differences in samples size (3 versus 8 
individuals) are likely to explain these differences. RT-qPCR was used to validate 11 of these 
miRNAs, of which six miRNAs, including miR-19b-3p and miR-107, were altered following 
exercise training in eight subjects (Fig. 10A). Expression of miR-19b-3p and miR-107 was 
also found to be increased after a single bout of exercise (Fig. 10B). The expression of these 
miRNAs continued to increase throughout the exercise training program and reached 
maximal levels by the end of the two-week training period (Fig. 10C-D). Although miR-107 
has previously been found to be induced following acute exercise in mice [199], this is the 
first report of miR-19b-3p and miR-107 responding to exercise training in humans. 
Figure 10. miRNA expression following endurance exercise and training. Healthy young males 
underwent a training program consisting of 1 hour of exercise at 80% VO2peak per day for 14 
consecutive days. Vastus lateralis skeletal muscle biopsies were collected prior to and following 1 
day, 10 days, and 14 days of exercise. A) Expression of miRNAs prior to (Baseline) and following 
exercise training (Trained) (n = 8). B) Expression of miRNAs prior to (Baseline) and after one bout of 
exercise (1 Day) (n = 5). C-D) Expression of C) miR-19b-3p and D) miR-107 prior to (Baseline) and 
following 10 and 14 days of exercise (n = 8). E) Expression of miRNAs in proliferating and 
differentiated human skeletal muscle cells (n = 3), # not detected in proliferating cells. Data are mean 
± SEM, determination performed by RT-qPCR. ‡ p < 0.05 determined by 2-way repeated measures 
ANOVA.*p < 0.05, **p < 0.01, ***p < 0.001 as determined by paired Student’s t-test or Sidak’s post 
hoc testing. 
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To determine if training-associated miRNAs were expressed in human skeletal 
muscle cultures in vitro, the expression of these miRNAs were profiled during human skeletal 
muscle cell differentiation. Nine out of the 11 miRNAs were expressed in human skeletal 
muscle cultures (Fig. 10E), and eight of these had increased expression in differentiated 
myotubes compared to proliferative myoblasts (miR-1-5p, miR-133-5p, and miR-378c were 
not detected in proliferative cells, and thus no fold change could be determined). Out of 
interest, these results were compared to data acquired in Study I. Expression of miR-103 and 
miR-107 was increased in both studies, while differences were observed for miR-19b and 
miR-30e (increased in Study III but unaltered in Study I). miR-22-5p was increased in 
Study III, but did only showed a trend for increased expression in Study I (p = 0.07). miR-1-
5p, miR-133a-5p, miR-378c, miR-223, and miR-451 were below the cut off of intensity 
levels used on the array data in Study I, in partial agreement with the results from Study III. 
Differences in methodology employed in the studies (i.e., RT-qPCR in Study III and miRNA 
arrays in Study I) could explain these divergent results. 
4.3.2 Functional effects of miR-19b-3p and miR-107 on glucose metabolism 
in human skeletal muscle cells 
To determine the functional effects of miR-19b-3p and miR-107 on exercise training-
associated adaptations in skeletal muscle, these miRNAs were overexpressed in human 
skeletal muscle cells. miR-19b-3p and miR-107 were chosen for functional characterization 
since expression was 1) altered by endurance training in human skeletal muscle, 2) detected 
in human cell cultures in vitro, and 3) still detected in mouse skeletal muscle following 
cardiac perfusion to remove blood-associated miRNA contamination from muscle. 
Overexpression of both miR-19b-3p and miR-107 increased basal and insulin-stimulated 
glucose uptake in cells (Fig. 11A-B). There is a significant interaction between miR-19b-3p 
overexpression and insulin treatment on glucose uptake (Fig. 11A), indicating potentiation of 
insulin sensitivity. These miRNAs also increased insulin-stimulated glucose incorporation 
into glycogen at two different insulin doses (Fig. 11C-D). Additionally, inhibition of these 
miRNAs in human skeletal muscle cells caused modest reductions in glucose uptake. Thus, 
miR-19b-3p and miR-107 improves glucose metabolism in human skeletal muscle cells. 
Overexpression of miR-19b-3p increased insulin-sensitive signaling as evidenced by 
increased phosphorylation of AktThr308 and AktSer473 under submaximal insulin stimulation. 
miR-19b-3p also increased phosphorylation at AS160Thr642 at baseline and following 10 nM 
insulin stimulation. This phosphorylation site in AS160 is insulin-responsive and required for 
insulin-stimulated glucose transport [200]. Our findings of enhanced insulin-stimulated Akt 
phosphorylation following miR-19b-3p overexpression are supported by findings 
highlighting miR-19b-3p as a positive regulator of Akt phosphorylation [201-203]. Findings 
of increased phosphorylation of Akt by miR-19b are associated with decreased expression of 
PTEN, a negative regulator of PI3K-mediated Akt activation [204]. miR-19b-3p decreased 
PTEN expression also in the current study. 
 36 
 
Figure 11. miR-19b-3p and miR-107 regulate glucose metabolism in human skeletal muscle 
cells. Human skeletal muscle cells were differentiated and transfected with a negative control (NC) 
miRNA precursor or miRNA precursors for miR-19b-3p and miR-107. A-B) Glucose uptake was 
determined at basal or 120 nM insulin following A) miR-19b-3p or B) miR-107 overexpression. C-D) 
Glucose incorporation into glycogen was determined Basal or 120 nM insulin following C) miR-19b-
3p or D) miR-107 overexpression. Data are mean ± SEM (n = 6). # miRNA effect; ¤ insulin effect; ϕ 
interaction; determined by 2-way ANOVA.*p < 0.05, **p < 0.01, and ***p < 0.001 as determined by 
Bonferroni post hoc testing. 
Similar to miR-19b-3p, miR-107 overexpression in human myotubes enhanced 
phosphorylation at AktThr308, AktSer473, and AS160Thr642 during treatment with 10 nM of 
insulin. Phosphorylation of Akt was also enhanced by 120 nM of insulin stimulation after 
miR-107 overexpression. These results are in line with a previous publication showing 
decreased phosphorylation of Akt following miR-107 inhibition in human cells [205]. Thus, 
increased glucose metabolism following miR-19b-3p and miR-107 overexpression is 
associated with enhanced insulin signaling. 
In mouse skeletal muscle cells, the effects on glucose metabolism of miR-19b-3p 
were conserved. In contrast, miR-107 failed to potentiate glucose uptake or glycogen 
synthesis in either primary mouse or C2C12 skeletal muscle cells. miR-107 negatively 
regulates insulin sensitivity in adipose tissue and liver in mice [109]. Divergent results of 
miR-107-regulated glucose uptake in human and mouse skeletal muscle cell could be due to 
differences in miRNA target conservation between human and mouse, or due to the decrease 
in myogenic markers associated with miR-107 overexpression in human skeletal muscle cells 
observed in the current study. Additionally, preliminary data from intact mouse FDB skeletal 
muscle indicate that overexpression of miR-19b-3p (but not miR-107) for one week 
potentiates contraction-induced glucose transport (glucose transport was enhanced in four out 
of five animals). In summary, miR-19b-3p, an endurance exercise training-induced miRNA, 
is a potent inducer of insulin and contraction-stimulated skeletal muscle glucose metabolism 
in both human and mouse tissues. 
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4.3.3 miR-19b-3p and miR-107-regulated target genes in human skeletal 
muscle following endurance exercise training  
Endurance exercise training potently alters the skeletal muscle transcriptome [136, 137]. 
Thus, studies were identified that reported transcriptomic responses in skeletal muscle from 
healthy humans to either training (paired analysis) [137, 206] or between subjects with 
different self-reported physical activity levels [207]. Overlapping gene expression signatures 
from these studies identified 5,817 genes that were regulated (p < 0.05) in at least two of the 
studies. Transcriptome analysis by gene arrays of human skeletal muscle cells subjected to 
either miR-19b-3p or miR-107 overexpression indicated regulation of 679 and 476 genes 
(fold-change cut off 1.5, p < 0.01), respectively. TargetScan and microRNA.org algorithms 
were used to identify predicted target genes of miR-19b-3p or miR-107. The identified 
predicted target genes were overlapped with the 5,817 genes altered by exercise training. This 
approached identified 26 genes which were downregulated due to miR-19b-3p 
overexpression and following exercise training. For miR-107, 18 predicted target genes met 
the same criteria employed for identification of miR-19b-3p-regulated genes. Selected 
predicted targets were validated to be downregulated following miR-19b-3p (Fig. 12A) or 
miR-107 (Fig. 12B) overexpression in human myotubes. All miR-19b-3p-regulated genes 
(except for Zbtb4) were found to be downregulated following overexpression in mouse 
skeletal muscle cells or tissue. Nevertheless, none of the miR-107 target genes altered in 
human cells was changed in mouse. Since these genes were indicated to be regulated by 
endurance training, the expression of miR-19b-3p and miR-107 predicted targets were 
measured genes in skeletal muscle following 14 consecutive days of exercise by RT-qPCR. 
Expression of CAV3, KIF13A, MAPK6, RNF11, and VPS37A were downregulated following 
exercise training (Fig. 12C). 
To determine if miR-19b-3p or miR-107 expression was correlated to expression of 
predicted target genes following exercise training, correlation analysis was performed. 
Expression levels of miR-19b-3p were negatively correlated to the expression of several 
target genes, including MAPK6 and RNF11 (Table 3 and Fig. 12D-E). miR-107 showed a 
significant negative correlation with the expression of three out of four target genes (Table 
3). Thus, expression levels of several genes are inversely correlated with miR-19b-3p or miR-
107 expression during skeletal muscle adaptation following exercise training, suggesting a 
role for miRNA-mediated regulation during this process. 
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Figure 12. Expression of miR-19b-3p and miR-107 predicted target genes in human skeletal 
muscle following endurance exercise training. Human skeletal muscle cells were differentiated and 
transfected with a negative control (NC) miRNA precursor or miRNA precursors for miR-19b-3p or 
miR-107. A-B) Expression of predicted target genes determined by RT-qPCR in human skeletal 
muscle cells following overexpression of either A) miR-19b-3p or B) miR-107 (n = 6). C) Expression 
of miR-19b-3p and miR-107 predicted target genes before (Baseline) or after 10 or 14 days of exercise 
(n = 8). D-E) Pearson correlation of miR-19b-3p expression to either D) MAPK6 or E) RNF11 
expression (n = 24). F) Human skeletal muscle cells were transfected either with a Scr control 
sequence or with siRNAs directed against MAPK6 or RNF11. Effects on basal and insulin-stimulated 
(120 nM Insulin) glucose uptake were determined (n = 3). Data are mean ± SEM. #p < 0.05 
determined by 2-way repeated measures ANOVA. *p < 0.05, **p < 0.01, and ***p < 0.001 following 
paired Student’s t-test or Sidak’s post hoc testing.  
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The functions of several of the genes with decreased expression following exercise 
training in skeletal muscle are unknown. MAPK6 is an atypical MAP kinase that exhibits 
increasing protein abundance during skeletal muscle cell differentiation [208]. RNF11 is 
essential to editing of ubiquitination in cells and has an Akt phosphorylation site [209], 
suggesting it might be responsive to Akt activation. Nevertheless, the function of these genes 
in regulation of insulin sensitivity or glucose metabolism is unknown. To determine the 
functional effect of MAPK6 and RNF11 on glucose metabolism, these genes were silenced by 
siRNA transfection in human skeletal muscle cells. Preliminary data indicate that RNF11 
silencing increased basal and insulin-stimulated glucose transport in all three subjects studied, 
while MAPK6 silencing was without any effect (Fig. 12F). Thus, decreased expression of 
RNF11 following exercise training is associated with increased glucose transport, one of the 
characteristic adaptations observed following endurance exercise training in skeletal muscle.  
Table 3. Correlation of miR-19b-3p or miR-107 to predicted targets in skeletal muscle. 
Pearson correlation of miRNA and gene expression in human skeletal muscle before or after ten or 
fourteen days of endurance exercise training. Gene expression was determined by RT-qPCR. 
Individual fold changes were calculated for each miRNA and gene, defined as expression level 
divided by average expression levels from Baseline, 10 days, and 14 days of training for the individual 
subject. r: Pearson’s correlation coefficient. n.s: non-significant. - : correlation was not performed 
since the gene is not a predicted target of the miRNA. *p < 0.05, **p < 0.01, and ***p < 0.001. 
In conclusion, miR-19b-3p and miR-107 are induced by endurance exercise training 
in skeletal muscle. miR-19b-3p increases glucose metabolism and insulin sensitivity in both 
human and mouse skeletal muscle, indicating conservation of its functions. Silencing of 
RNF11, a gene decreased by miR-19b-3p overexpression and training, enhanced glucose 
uptake in human skeletal muscle cells. Thus, miR-19b-3p-dependent regulation of RNF11 in 
human skeletal muscle could be an adaptive response of skeletal muscle to promote glucose 
uptake following endurance exercise training. 
Gene symbol miR-19b-3p miR-107 
r p-value r p-value 
CAV3 - - -0.572 ** 
CLIP4 -0.738 *** - - 
FAM98A - - -0.244 n.s 
HBP1 -0.709 *** - - 
KIF13A -0.715 *** 0.631 *** 
MAPK6 -0.744 *** - - 
RNF11 -0.441 * - - 
SLAIN2 - - -0.540 ** 
VPS37A -0.628 ** - - 
ZBTB4 -0.636 *** - - 
ZDHHC7 -0.373 n.s - - 
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5 CONCLUSION AND FUTURE PERSPECTIVES 
5.1 CONCLUDING REMARKS 
The three studies included in this thesis have focused on the roles of miRNAs as post-
transcriptional regulators in skeletal muscle. See Figure 13 for a summarizing overview of 
findings presented in this thesis. In all studies, expression of miRNAs has been determined in 
skeletal muscle biopsies or cells of human origin. This led to the identification of several 
novel miRNAs that are altered during the process of cell differentiation, dysregulated with 
T2D (miR-29 family members), and induced by endurance exercise training (miR-19b-3p 
and miR-107). Nevertheless, because changes of miRNAs expression do not directly imply 
functional alterations [210], an important aspect of miRNA research is the identification of 
their target genes. 
Figure 13. Highlighted findings reported on in this thesis. In this thesis, altered expression of 
miRNAs was identified in three different biological conditions or disease states. Target genes of 
differentially regulated miRNAs were predicted in silico and changes in mRNA or protein abundance 
was determined. Also, direct regulation of target genes was inferred by luciferase assay. Direct 
regulation of biological processes by altered miRNAs was studied in vitro and in vivo. 
All studies reported herein aimed to identify targets of the differentially regulated 
miRNAs. In Study I, mRNA and miRNA expression in skeletal muscle cells during 
differentiation were measured with transcriptomic resolution to develop in silico-based 
models of miRNA-centered regulatory networks. In Study II, predicted miR-29 targets were 
identified using in silico algorithms. In Study III, transcriptomic data following 
overexpression of miR-19b-3p or miR-107 was overlapped with publicly available 
transcriptomic data sets to identify miRNA-predicted targets that are differentially expressed 
according to aerobic fitness. miRNA target prediction algorithms are useful tools to predict 
potential targets, but unfortunately in silico predictions typically generate large numbers of 
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false positives. Thus, experimentally elucidating functional effects of differentially regulated 
miRNAs in relevant models is necessary to augment the validity of in silico prediction of 
miRNA targets and functions. 
To this end, in addition to predicting targets of miRNA that were differentially 
regulated in skeletal muscle, this thesis also aimed to determine direct functional effects of 
these miRNAs. Targets of miRNAs are generally well conserved between species [211]. 
Nevertheless, a majority of functional perturbation experiments presented herein originated 
from skeletal muscle cell cultures of human origin that increase the translational impact of 
our data. The altered miRNA expression was connected to functional aspects in each 
condition being studied, including identification of potential miRNA-centered regulatory 
networks during differentiation, and alterations of insulin sensitivity and glucose metabolism 
with training and in T2D. In Study I, direct regulation of miR-30b and miR-30c on 
expression of RASAL2 was identified, with a reciprocal relationship between miR-30 
expression found during differentiation. In Study II, impaired glucose uptake following miR-
29a or miR-29c overexpression was associated with decreased HK2 expression and 
hexokinase activity. HK2 expression tended to be decreased in skeletal muscle of T2D 
patients, and HK2 expression in skeletal muscle of healthy NGT and diabetic subjects was 
associated with increased miR-29c expression. Additionally, in Study III, miR-19b-3p and 
miR-107 regulate some of the endurance training-associated adaptations in skeletal muscle, 
including improved insulin sensitivity and glucose transport. Interestingly, an endurance 
training-regulated gene, RNF11, altered glucose transport similarly to miR-19b-3p and 
mimicked the response of training on glucose metabolism. Thus, in this study, I propose miR-
19b-3p to be a potential regulator of endurance training-mediated potentiation of glucose 
transport. 
The use of human in vitro models is essential to study direct effects of miRNAs in the 
context of human genetics. Yet, results generated from in vitro experiments are not directly 
translatable to clinical practice. To address this limitation, in Study II–III, the effects of the 
studied miRNAs on target regulation and metabolism were determined in intact mouse 
skeletal muscle. In Study II, skeletal muscle glucose metabolism was decreased in vivo 
following overexpression of miR-29a or -29c. In Study III, miR-19b-3p effects were 
conserved between human and mouse, and preliminary data indicate that overexpression of 
this miRNA in intact skeletal muscle of mice increased contraction-induced glucose uptake in 
4 out of 5 subjects studied. The approach of combining human in vitro and mouse in vivo 
models increases the strength of our findings. Nevertheless, further additional experiments to 
those presented herein could bolster the translatability of our findings to human physiology. 
For example, in Study I, experiments designed to inhibit endogenous miR-30b or miR-30c to 
determine the regulation or the function of these miRNAs and their targets during skeletal 
muscle cell differentiation were not performed. Conclusions related to the miR-29-mediated 
effects on metabolism in Study II could have been strengthened by determining whether 
normalization of increased expression levels of miR-29, due to palmitate treatment in cells or 
in ob/ob skeletal muscle tissue of mice, could enhance insulin sensitivity in these conditions. 
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Additionally, in Study III, determining all relevant endogenous targets of miR-19b-3p or 
miR-107 could yield further insights. Since these miRNAs were induced following endurance 
training, determining their direct roles in vivo on endurance training adaptation-associated 
traits would be of interest. Our preliminary data indicates increased ex vivo contraction-
stimulated glucose uptake following miR-19b-3p overexpression in intact skeletal muscle of 
mice, however additional experiments are needed to support these conclusions. 
To advance the field of miRNA research in skeletal muscle, the focus of future 
research should shift from determining changed abundance of miRNAs toward resolving 
alterations in miRNA activities, which could be inferred, for example, by HITS-CLIP. 
Advances in genetic editing, such as CRISPR [176], could be used to directly determine roles 
of miRNAs on functional aspects of biology both in vitro and in vivo. 
In conclusion, results presented in this thesis identified novel miRNAs altered during 
skeletal muscle maturation, insulin resistance and exercise training adaptation. Altogether, 
this work identifies miRNAs as potent regulators of functions important for skeletal muscle 
adaptability and disease. 
5.2 miRNA AS THERAPEUTICS IN SKELETAL MUSCLE 
As the abundance of various miRNAs are altered in skeletal muscle from several disease 
states, including cancer cachexia [212], atrophy [177], and diabetes (as shown in this thesis), 
pharmacological interference of dysfunctional miRNA expression could have attractive 
therapeutic potential. Initial trials with deliveries of miRNA mimics were ineffective due to 
degradation and inefficient delivery to targeted tissues [213]. Improved stability of miRNAs 
by chemical modifications, for example by using locked nucleic acids (LNA), has been 
achieved [214]. Targeting of skeletal muscle is complicated by the fact that it has a relatively 
large volume and low muscle selectivity was achieved with earlier delivery methods. High 
pharmacological doses might result in off-site effects, and safety of therapies using miRNA 
inhibitors or mimics have to be demonstrated: adverse events terminated a phase I clinical 
trial investigating the effects of a miR-34 mimic (MRX34) in cancer treatment. In mice, 
oligonucleotide-based delivery resulted in successful gene suppression in skeletal muscle 
[215]. In addition, chemical modifications are being tested to improve the selectivity of these 
oligonucleotides for delivery into skeletal muscle. For example, a recent study reported that 
oligonucleotide modifications using specific RNA aptamers improved muscle selectivity in 
vivo in mice [216]. Nevertheless, such treatment strategies demand validation in humans, 
particularly if the goal is to treat T2D given the chronic condition of this disease. Adeno-
associated viruses of different serotypes can also be used to achieve tissue enrichment, and 
applications using tissue-specific promotors can reduce expression in non-targeted tissues. 
Adeno-associated viruses are employed in clinical trials for intramuscular injection and 
targeting of delivery to skeletal muscle [217]. Thus, specific targeting of skeletal muscle 
tissue can be achieved. In perspective of findings reported in this thesis and previous 
publications [187], miR-29 members, that are increased in insulin resistant tissues, could be 
attractive pharmaceutical targets. 
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